| Literature DB >> 21340214 |
Gabriela Gualco1, Claudete E Klumb, Glen N Barber, Lawrence M Weiss, Carlos E Bacchi.
Abstract
OBJECTIVE: This study provides the clinical pathological characteristics of 1301 cases of pediatric/adolescent lymphomas in patients from different geographic regions of Brazil.Entities:
Mesh:
Year: 2010 PMID: 21340214 PMCID: PMC3020336 DOI: 10.1590/s1807-59322010001200008
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Primary antibodies used for immunohistochemical staining in paraffin sections.
| Antigen | Clone | Dilution | Antigen retrieval | Source |
| CD20 | L26 | 1∶1200 | MW; CB | Dako |
| CD3 | SP7 | 1∶200 | S; CB | Neomarkers |
| CD30 | BerH2 | 1∶100 | S; CB | Dako |
| Granzime | Gran‐B | 1∶40 | MW; CB | Novocastra |
| TIA‐1 | 2G9 | 1∶200 | MW, CB | Immunotech |
| Ki‐67 | MIB‐1 | 1∶4800 | PC; CB | Dako |
| LMP‐1 | CS1‐4 | 1∶2000 | S; CB | Dako |
| CD45RB | PD7 | 1∶500 | MW;CB | Dako |
| CD15 | Leu‐M1 | 1∶50 | MW; CB | Becton‐Dickinson |
| CD10 | 56C6 | 1∶100 | S; CB | Novocastra |
| BCL‐2 | 124 | 1∶400 | MW; CB | Dako |
| BCL‐6 | PG‐B6P | 1∶100 | T+ S; TRIS | Dako |
| IRF4/MUM‐1 | MUM1P | 1∶1200 | S; CB | Dako |
| ALK | ALK‐1 | 1∶200 | S; TRIS | Dako |
| EMA | E29 | 1∶800 | PC; CB | Dako |
| PAX‐5 | 24 | 1∶100 | S; CB | Becton‐Dickinson |
| CD25 | 4C9 | 1∶200 | S; EDTA | Novocastra |
| CD23 | SP23 | 1∶400 | MW; CB | Neomarkers |
| CD5 | 4C7 | 1∶1600 | S; CB | Novocastra |
| TDT | Polyclonal | 1∶600 | S; CB | Dako |
| Cyclin D1 | SP4 | 1∶100 | S; CB | Neomarkers |
| Ki‐67 | MIB‐1 | 1∶4800 | PC; CB | Dako |
DAKO, Carpinteria, CA, USA; Neomarkers, Fremont, CA, USA, Novocastra, United Kingdom; Abcam, San Francisco, CA, USA; RD, Minneapolis, MN, USA: Immunotech, Marseille, France; Becton‐Dickinson Biosciences, Mountain View, CA, USA. Heat‐induced epitope retrieval was employed. MW: microwave oven, PC: pressure cooker, S: steamer, T: trypsin, CB: citrate buffer.
Figure 1A, Global distribution of non‐Hodgkin and Hodgkin pediatric lymphoma cases in Brazil. B, Distribution of all cases of pediatric lymphoma by age groups. C, Distribution of all cases of pediatric lymphoma by gender.
Overview of all cases of pediatric lymphomas distributed by geographic region according to mean age, age range, gender, and lymphoma subtype.
| N 114 (8.8%) | NE 373 (28.7%) | CW 105 (8%) | S 209 (16.1%) | SE 500 (38.4%) | |
| Age | |||||
| Mean (y) | 9.7 | 10.9 | 11.2 | 12.4 | 10.9 |
| Range (y) | 1–18 | 1–18 | 3–18 | 1–18 | 1–18 |
| Gender | |||||
| Male | 79 | 255 | 61 | 123 | 328 |
| Female | 35 | 118 | 44 | 86 | 172 |
| Lymphoma type | |||||
| NHL | 57 (50%) | 212 (57%) | 62 (59%) | 138 (66%) | 286 (57%) |
| HL | 57 (50%) | 161 (43%) | 43 (41%) | 71 (34%) | 214 (43%) |
N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast; NHL: non‐Hodgkin lymphoma; HL: Hodgkin lymphoma; y: years.
Precursor lymphoid neoplasms in pediatric patients classified according to cell lineage, gender, and geographical region distribution for each lineage group.
| Region | LL B cell | LL T cell | LL unclassified | ||||||
| Cases (%) | F | M | Total (%) | F | M | Total (%) | F | M | Total (%) |
| N 19 (7) | 1 | 2 | 3 (4.3) | 6 | 8 | 14 (8.7) | 0 | 2 | 2 (4.7) |
| NE 64 (23.5) | 6 | 10 | 16 (23.2) | 12 | 30 | 42 (26) | 4 | 2 | 6 (14.3) |
| CW 20 (7.3) | 2 | 2 | 4 (5.8) | 3 | 8 | 11 (6.8) | 3 | 2 | 5 (12) |
| S 63 (23.2) | 13 | 6 | 19 (27.5) | 10 | 18 | 28 (17.3) | 2 | 14 | 16 (38) |
| SE 106 (39) | 9 | 18 | 27 (39) | 18 | 48 | 66 (41) | 5 | 8 | 13 (31) |
| Total | 31 | 38 | 69 (100) | 49 | 112 | 161 (100) | 14 | 28 | 42 (100) |
N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast; LL: lymphoblastic lymphoma; F: female; M: male.
Figure 2Pediatric mature non‐Hodgkin lymphoid neoplasm. A, Global distribution according to cell lineage. B, Specific distribution according to main subtypes.
Mature B‐cell lymphoma in pediatric patients, distribution by gender and geographical areas for each subtype
| BL | DLBCL | Unclassif | MZL | ||||||||||
| F | M | T (%) | F | M | T (%) | F | M | T (%) | F | M | T (%) | Total | |
| N | 9 | 17 | 26 (9.3) | 2 | 3 | 5 (5.4) | 1 | 0 | 1 (8.3) | 0 | 0 | 0 | 32 (8.2) |
| NE | 18 | 65 | 83 (29.5) | 6 | 21 | 27 (29.3) | 2 | 0 | 2 (16.6) | 0 | 1 | 1 (25) | 114 (29.2) |
| CW | 11 | 15 | 26 (9.3) | 1 | 4 | 5 (5.4) | 0 | 1 | 1 (8.3) | 1 | 1 | 2 (50) | 34 (8.7) |
| S | 9 | 30 | 39 (13.9) | 7 | 8 | 15 (16.4) | 1 | 3 | 4 (33.3) | 0 | 0 | 0 | 58 (14.9) |
| SE | 28 | 79 | 107 (38) | 12 | 28 | 40 (43.5) | 3 | 1 | 4 (33.3) | 1 | 0 | 1 (25) | 152 (39) |
| Total | 75 | 206 | 281 (100) | 28 | 64 | 92 (100) | 7 | 5 | 12 (100) | 2 | 2 | 4 (100) | 390 (100) |
N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast; F: female; M: male; BL: Burkitt lymphoma; DLBCL: diffuse large B‐cell lymphoma; MZL: marginal zone lymphoma; the only case of follicular lymphoma was a boy from NE region.
Geographic distribution of mature T‐cell lymphomas in pediatric patients
| ALCL‐ALK+ | ALCL‐ALK‐ | PTLC‐NOS | T/NK | Other | ||||||||||||
| Region | F | M | T (%) | F | M | T (%) | F | M | T (%) | F | M | T (%) | F | M | T (%) | Total |
| N | 0 | 2 | 2 (3.8) | 0 | 1 | 1 (11.1) | 1 | 1 | 2 (8.7) | 0 | 1 | 1 (20) | 0 | 0 | 0 | 6 (6.4) |
| NE | 6 | 13 | 19 (35.8) | 0 | 2 | 2 (22.2) | 3 | 3 | 6 (26) | 0 | 2 | 2 (40) | 1 | 1 | 2 (66.6) | 31(33.3) |
| CW | 2 | 2 | 4 (7.6) | 0 | 0 | 0 | 1 | 2 | 3 (13) | 0 | 0 | 0 | 0 | 1 | 1 (33.3) | 8 (8.6) |
| S | 5 | 5 | 10 (18.9) | 3 | 1 | 4 (44.4) | 3 | 1 | 4 (17.4) | 1 | 0 | 1 (20) | 0 | 0 | 0 | 19 (20.4) |
| SE | 9 | 9 | 18 (33.9) | 0 | 2 | 2 (22.2) | 3 | 5 | 8 (34.8) | 1 | 0 | 1 (20) | 0 | 0 | 0 | 29 (31.2) |
| Total | 22 | 31 | 53 (100) | 3 | 6 | 9 (100) | 11 | 12 | 23 (100) | 2 | 3 | 5 (100) | 1 | 2 | 3 (100) | 93 (100) |
N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast; F: female; M: male; ALCL‐ALK+ anaplastic large cell lymphoma; ALK‐ positive; ALCL‐ALK‐: anaplastic large cell lymphoma ALK‐ negative; PTCL‐NOS: peripheral T‐cell lymphoma, no‐otherwise specified; T/NK: T/NK cell‐ lymphoma nasal type.
Figure 3Comparative distribution of all types of pediatric non‐Hodgkin lymphomas separated by age group. TCL: T‐cell lymphoma; ALCL: anaplastic large cell lymphoma; ALK: anaplastic large cell lymphoma kinase; Unclass: unclassified; DLBCL: diffuse large B‐cell lymphoma; BL: Burkitt lymphoma; LL: lymphoblastic lymphoma.
Figure 4Comparative distribution of all cases of pediatric lymphomas by age groups in each geographic region. N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast.
Figure 5Hodgkin lymphoma distribution. CHL: classic Hodgkin lymphoma; NLPHL: nodular lymphocyte predominant Hodgkin lymphoma.
Geographic distribution of pediatric Hodgkin lymphoma.
| CHL | NLP | All cases HL | |
| N | 45 (79%) | 12 (21%) | 57 (100%) |
| NE | 136 (84%) | 25 (16%) | 161 (100%) |
| CO | 38 (88%) | 5 (12%) | 43 (100%) |
| S | 63 (89%) | 8 (11%) | 71 (100%) |
| SE | 194 (91%) | 20 (9%) | 214 (100%) |
CHL: classical Hodgkin lymphoma; NLP: nodular lymphocyte predominant Hodgkin lymphoma; HL: Hodgkin lymphoma; N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast.
Geographic distribution of CHL morphologic subtypes.*
| NS | MC | LD | LR | |||||||||
| Region | F | M | S/T | F | M | S/T | F | M | S/T | F | M | S/T |
| N | 9 | 23 | 32 | 4 | 6 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| NE | 43 | 55 | 98 | 9 | 19 | 28 | 1 | 2 | 3 | 0 | 2 | 2 |
| CW | 16 | 15 | 31 | 2 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| S | 28 | 22 | 50 | 3 | 9 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| SE | 76 | 74 | 150 | 3 | 35 | 38 | 0 | 0 | 0 | 2 | 1 | 3 |
| T | 172 | 189 | 361 | 21 | 71 | 92 | 1 | 2 | 3 | 2 | 3 | 5 |
15 unclassified cases are not included in the table. NS: nodular sclerosis; MC: mixed cellularity; LD: lymphocyte depletion; LR: lymphocyte rich; M: male; F: female; S/T: subtotal of each subgroup; T: total; N: North; NE: Northeast; CW: Central‐West; S: South; SE: Southeast.
Figure 6Classical Hodgkin lymphoma and nodular predominance lymphocyte Hodgkin lymphoma distribution in all age groups.
Distribution of pediatric classical Hodgkin morphologic subtypes according to age.
| Age (years) | NS (%) | MC (%) | LD (%) | LR (%) | U (%) | Total (%) |
| 0–5 | 14 (66.6) | 6 (28.6) | 0 | 0 | 1 (4.8) | 21 (100) |
| 6–10 | 63 (61.2) | 30 (29.2) | 1 (0.9) | 2 (1.9) | 7 (6.8) | 103 (100) |
| 11–14 | 91 (72.8) | 27 (21.6) | 1 (0.8) | 2 (1.7) | 4 (3.2) | 125 (100) |
| 15–18 | 193 (85) | 29 (12.8) | 1 (0.4) | 1 (0.4) | 3 (1.2) | 227 (100) |
| Total | 361 (75.8) | 92 (19.3) | 3 (0.6) | 5 (1) | 15 (3.2) | 476 (100) |
NS: nodular sclerosis; MC: mixed cellularity; LD: lymphocyte depletion; LR: lymphocyte rich; U: unclassified.
Figure 7Distribution of all cases of pediatric lymphomas according to geographic regions. A: North, B: Northeast, C: Central‐West, D: SouthE, Southeast. LL: lymphoblastic lymphoma; BL: Burkitt lymphoma; DLBCL: diffuse large B‐cell lymphoma; Unclass: unclassified; ALCL: anaplastic large cell lymphoma; ALK: anaplastic large cell lymphoma kinase; T/NK nasal: T/K lymphoma “nasal type”; T‐NOS: peripheral T‐cell lymphoma not otherwise specified; NLP: nodular lymphocyte predominant; CHL: classic Hodgkin lymphoma.
Figure 8Overall distribution of the most frequent pediatric lymphomas according to main geographic regions in Brazil.
Footnote: LL: lymphoblastic lymphoma; BL: Burkitt lymphoma; ALCL: anaplastic large cell lymphoma; HL: Hodgkin lymphoma.